Data as of 3:59pm ET
| -0.0203 / -0.28%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 4.10, with a high estimate of 8.92 and a low estimate of 3.74. The median estimate represents a -43.03% decrease from the last price of 7.19.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.